Research Analysts’ Weekly Ratings Changes for Rhythm Pharmaceuticals (RYTM)

A number of research firms have changed their ratings and price targets for Rhythm Pharmaceuticals (NASDAQ: RYTM):

• 3/18/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $64.00 to $66.00. They now have a “buy” rating on the stock.
• 3/7/2025 – Rhythm Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $72.00 price target on the stock.
• 3/5/2025 – Rhythm Pharmaceuticals is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $78.00 price target on the stock.
• 3/3/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at HC Wainwright from $69.00 to $70.00. They now have a “buy” rating on the stock.
• 2/27/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Canaccord Genuity Group Inc. from $80.00 to $81.00. They now have a “buy” rating on the stock.
• 2/27/2025 – Rhythm Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
• 2/19/2025 – Rhythm Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.

Rhythm Pharmaceuticals Price Performance

Shares of Rhythm Pharmaceuticals stock traded down $1.36 on Thursday, hitting $53.85. 347,539 shares of the company’s stock traded hands, compared to its average volume of 484,682. The company has a market capitalization of $3.40 billion, a price-to-earnings ratio of -12.44 and a beta of 2.30. The company has a fifty day moving average of $55.51 and a two-hundred day moving average of $54.81. Rhythm Pharmaceuticals, Inc. has a one year low of $35.17 and a one year high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The company had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Equities research analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 635 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the sale, the chief accounting officer now owns 2,070 shares of the company’s stock, valued at approximately $118,445.40. This trade represents a 23.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Yann Mazabraud sold 75,000 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $51.48, for a total value of $3,861,000.00. Following the transaction, the executive vice president now directly owns 40,370 shares in the company, valued at $2,078,247.60. The trade was a 65.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,787 shares of company stock valued at $5,762,443. Corporate insiders own 5.60% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at about $4,259,000. GF Fund Management CO. LTD. acquired a new position in Rhythm Pharmaceuticals during the 4th quarter valued at about $72,000. Voloridge Investment Management LLC increased its holdings in Rhythm Pharmaceuticals by 7.7% during the 4th quarter. Voloridge Investment Management LLC now owns 380,537 shares of the company’s stock worth $21,302,000 after purchasing an additional 27,214 shares in the last quarter. Two Sigma Advisers LP raised its stake in shares of Rhythm Pharmaceuticals by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 13,100 shares of the company’s stock worth $733,000 after purchasing an additional 300 shares during the last quarter. Finally, State of Wyoming bought a new position in shares of Rhythm Pharmaceuticals in the fourth quarter valued at approximately $61,000.

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.